In this pilot study, we aim to prospectively screen for the BRAF (V600E) mutations in the plasma of patients undergoing surgery for thyroid nodules to assess the sensitivity and accuracy of ctDNA for the detection of thyroid cancer and to evaluate its value as a tool for thyroid cancer surveillance. This evidence concerns the gene BRAF and thyroid gland carcinoma.